The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) ...

Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe ...

NBCC: The company has successfully sold 446 residential units at Aspire Silicon City in Noida through an e-auction, generating Rs 1,468 crore in sales. Additionally, it will receive a marketing fee of ...

Microsoft launches Discovery platform that uses agentic AI to compress years of scientific research into days, transforming R&D across pharmaceuticals, materials science, and semiconductor industries.

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...

Microsoft Corp. today announced the launch of Microsoft Discovery, a new enterprise-grade artificial intelligence platform ...

23andMe was founded 19 years ago to provide saliva-based genetic testing of health and ancestry to consumers, going public in ...